0001144204-17-012052.txt : 20170301 0001144204-17-012052.hdr.sgml : 20170301 20170301140639 ACCESSION NUMBER: 0001144204-17-012052 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170301 DATE AS OF CHANGE: 20170301 EFFECTIVENESS DATE: 20170301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XTL BIOPHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001023549 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-281565 FILM NUMBER: 17653192 BUSINESS ADDRESS: STREET 1: XTL BIOPHARMACEUTICALS LTD STREET 2: C/O ALSTON & BIRD LLP, 90 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 972 9 955 7080 MAIL ADDRESS: STREET 1: 5 HACHAROSHET ST. CITY: RAANANA STATE: L3 ZIP: 4365603 D 1 primary_doc.xml X0707 D LIVE 0001023549 XTL BIOPHARMACEUTICALS LTD 5 HACHAROSHET ST. RAANANA L3 ISRAEL 4365603 972 9 955 7080 ISRAEL None None Corporation true Shlomo Shalev 5 Hacharoshet St. Raanana L3 ISRAEL 4365603 Director Chairman of the Board of Directors Ossi Hillel Fain 5 Hacharoshet St. Raanana L3 ISRAEL 4365603 Director Non-Executive and External Director Oded Nagar 5 Hacharoshet St. Raanana L3 ISRAEL 4365603 Director Non-Executive and External Director David Bassa 5 Hacharoshet St. Raanana L3 ISRAEL 4365603 Director Non-Executive Director Doron Turgeman 5 Hacharoshet St. Raanana L3 ISRAEL 4365603 Director Non-Executive Director Jonathan Schapiro 5 Hacharoshet St. Raanana L3 ISRAEL 4365603 Director Non-Executive Director Dobroslav Melamed 5 Hacharoshet St. Raanana L3 ISRAEL 4365603 Director Non-Executive Director Joshua Levine 5 Hacharoshet St. Raanana L3 ISRAEL 4365603 Executive Officer Chief Executive Officer David Kestenbaum 5 Hacharoshet St. Raanana L3 ISRAEL 4365603 Executive Officer Chief Financial Officer Pharmaceuticals Decline to Disclose 06b false 2017-02-17 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE, 4TH FLOOR NEW YORK NY NEW YORK 10022 CA CALIFORNIA IL ILLINOIS NJ NEW JERSEY NY NEW YORK false 2500000 2500000 0 The warrants and shares underlying the warrants, the subject matter of this Form D, were issued in connection with an offering of (i) 1,000,000 ADSs issued in a registered direct offering; and (ii) unregistered warrants to purchase 1,000,000 ADSs. false 5 175000 true 0 H.C. Wainwright & Co. is also entitled to receive a cash management fee of $25,000, plus an expense reimbursement of $35,000. H.C. Wainwright & Co. will also receive warrants to purchase up to 50,000 of the ADSs exercisable at $4.10 per ADS. 0 The Issuer expects to use proceeds from the offering for working capital purposes, which include payment of salaries and bonuses to named executive officers estimated at $55,000. false XTL BIOPHARMACEUTICALS LTD /s/ Josh Levine Josh Levine CEO 2017-03-01